𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Non-Hodgkin's lymphoma and agricultural use of the insecticide lindane

✍ Scribed by Aaron Blair; Kenneth P. Cantor; Shelia Hoar Zahm


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
44 KB
Volume
33
Category
Article
ISSN
0271-3586

No coin nor oath required. For personal study only.

✦ Synopsis


Data from population-based case-control studies of non-Hodgkin's lymphoma among white men from Kansas, Nebraska, Iowa, and Minnesota were pooled to evaluate potential risks from environmental exposures in more detail, while controlling for potential confounding factors. These data provided the opportunity to evaluate the risk of non-Hodgkin's lymphoma from potential exposures to lindane, a pesticide that causes cancer in laboratory animals and has been associated with human cancer in a few epidemiologic investigations. This pooled data set includes 987 individuals with non-Hodgkin's lymphoma and 2,895 population-based controls. Information was obtained by telephone or in person interviews, which included detailed questions on farm practices and agricultural use of chemicals. Logistic regression was used to calculate odds ratios (ORs) adjusted for age, state of residence, and subject or proxy interviews. Reported use of lindane significantly increased the risk of non-Hodgkin's's lymphoma by 50%. Some use characteristics were suggestive of an association. ORs were greater among persons who first used the pesticide 20 years before diagnosis (OR Ο­ 1.7) than more recently (OR Ο­ 1.3), among those who reported more frequent use (OR Ο­ 2.0 for use 5 or more days per year versus 1.6 for fewer than five days per year), and from use on crops (OR Ο­ 1.9), rather than from use on animals (OR Ο­ 1.3), although these differences were not statistically significant. On the other hand, ORs were lower when based on direct interviews (OR Ο­ 1.3) than on data from proxy respondents (OR Ο­ 2.1) and adjustment for potential confounding by use of 2,4-D and diazinon reduced the ORs associated with lindane use from 1.5 to 1.2 and 1.3, respectively. Lindane does not appear to be a major etiologic factor in the development of non-Hodgkin's's lymphoma, although a small role cannot be ruled out.Am.


πŸ“œ SIMILAR VOLUMES


The treatment of non-Hodgkin's lymphoma
✍ Samuel Hellman; David S. Rosenthal; William C. Moloney; John T. Chaffey πŸ“‚ Article πŸ“… 1975 πŸ› John Wiley and Sons 🌐 English βš– 432 KB πŸ‘ 2 views

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and pos

Chemotherapy of the non-Hodgkin's lympho
✍ Dr. George P. Canellos; T. Andrew Lister; Arthur T. Skarin πŸ“‚ Article πŸ“… 1978 πŸ› John Wiley and Sons 🌐 English βš– 818 KB
Role of laparoscopy for Hodgkin's and no
✍ R. Matthew Walsh; B. Todd Heniford πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 421 KB πŸ‘ 2 views

An efficacious approach to the diagnosis and treatment of lymphoma requires the expertise of both physicians and surgeons. The surgeon frequently is required to provide an adequate tissue diagnosis, stage the disease, and treat complications of the disease such as splenomegaly. Often, abdominal and

History of antibiotic use and risk of no
✍ Ikuko Kato; Karen L. Koenig; Mark S. Baptiste; Patricia P. Lillquist; Glauco Fri πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 89 KB

## Abstract A population‐based, incidence case‐control study was conducted among women in upstate New York to determine whether histories of certain infections and antibiotic use are associated with risk of non‐Hodgkin's lymphoma (NHL). Our study involved 376 cases of NHL identified through the New